Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
65
REGN Quote, Financials, Valuation and Earnings
Last price:
$800.87
Seasonality move
:
3.83%
Day range:
$780.10 - $814.10
52-week range:
$476.49 - $814.10
Dividend yield:
0.43%
P/E ratio:
19.45x
P/S ratio:
6.28x
P/B ratio:
2.76x
Volume:
1.3M
Avg. volume:
895.8K
1-year change:
11.22%
Market cap:
$85.4B
Revenue:
$14.2B
EPS (TTM):
$41.77
Analysts' Opinion
-
Consensus RatingRegeneron Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $804.96, Regeneron Pharmaceuticals, Inc. has an estimated downside of -0.9% from its current price of $812.27.
-
Price Target UpsideAccording to analysts, the highest upside price target is $1,057.00 representing 30.13% upside increase from its current price of $812.27.
Fair Value
-
According to the consensus of 23 analysts, Regeneron Pharmaceuticals, Inc. has -0.9% downside to fair value with a price target of $804.96 per share.
REGN vs. S&P 500
-
Over the past 5 trading days, Regeneron Pharmaceuticals, Inc. has overperformed the S&P 500 by 4.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Regeneron Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Regeneron Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Regeneron Pharmaceuticals, Inc. reported revenues of $3.8B.
Earnings Growth
-
Regeneron Pharmaceuticals, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Regeneron Pharmaceuticals, Inc. reported earnings per share of $13.62.
Enterprise value:
79.6B
EV / Invested capital:
--
Price / LTM sales:
6.28x
EV / EBIT:
20.79x
EV / Revenue:
5.59x
PEG ratio (5yr expected):
5.78x
EV / Free cash flow:
20.52x
Price / Operating cash flow:
23.06x
Enterprise value / EBITDA:
18.28x
Gross Profit (TTM):
$11.6B
Return On Assets:
11.97%
Net Income Margin (TTM):
32.13%
Return On Equity:
15.37%
Return On Invested Capital:
14.07%
Operating Margin:
29.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $13.1B | $13.8B | $14.2B | $3.7B | $3.8B | |
| Gross Profit | $11B | $11.5B | $11.6B | $3.1B | $3.1B | |
| Operating Income | $4.5B | $4.1B | $3.8B | $1.2B | $1.1B | |
| EBITDA | $5B | $4.6B | $4.4B | $1.4B | $1.2B | |
| Diluted EPS | $35.06 | $40.41 | $41.77 | $11.54 | $13.62 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.8B | $15.4B | $18.6B | $19.3B | $18B | |
| Total Assets | $23.7B | $27.7B | $32.2B | $37.4B | $40.2B | |
| Current Liabilities | $3.7B | $2.9B | $3.6B | $3.7B | $4.4B | |
| Total Liabilities | $6.4B | $6.2B | $7.3B | $8.1B | $9.2B | |
| Total Equity | $17.3B | $21.4B | $24.9B | $29.3B | $31B | |
| Total Debt | $2.7B | $2.7B | $2.7B | $2.7B | $2.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.2B | $4.2B | $5.1B | $1.3B | $1.6B | |
| Cash From Investing | -$5B | -$2.9B | -$498.8M | -$574.4M | -$402.9M | |
| Cash From Financing | -$1.6B | -$1.5B | -$4.1B | -$634M | -$717.9M | |
| Free Cash Flow | $4.4B | $3.3B | $3.9B | $1B | $1.4B | |
REGN
Sector
Market Cap
$85.4B
$28.8M
Price % of 52-Week High
99.78%
52.28%
Dividend Yield
0.43%
0%
Shareholder Yield
5.94%
-1.55%
1-Year Price Total Return
11.22%
-18.69%
Beta (5-Year)
0.390
0.497
Dividend yield:
0.43%
Annualized payout:
$0.00
Payout ratio:
6.46%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$779.95
200-day SMA
Buy
Level
$606.13
Bollinger Bands (100)
Buy
Level
566.78 - 733.06
Chaikin Money Flow
Buy
Level
76.9M
20-day SMA
Buy
Level
$763.01
Relative Strength Index (RSI14)
Buy
Level
69.50
ADX Line
Buy
Level
27.31
Williams %R
Sell
Level
-2.4442
50-day SMA
Buy
Level
$723.52
MACD (12, 26)
Buy
Level
18.93
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
43.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.8896)
Buy
CA Score
(Annual)
Level (1.5047)
Buy
Beneish M-Score
(Annual)
Level (-2.3303)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-4.4994)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Stock Forecast FAQ
In the current month, REGN has received 15 Buy ratings 8 Hold ratings, and 0 Sell ratings. The REGN average analyst price target in the past 3 months is $804.96.
-
Where Will Regeneron Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Regeneron Pharmaceuticals, Inc. share price will drop to $804.96 per share over the next 12 months.
-
What Do Analysts Say About Regeneron Pharmaceuticals, Inc.?
Analysts are divided on their view about Regeneron Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regeneron Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $627.00.
-
What Is Regeneron Pharmaceuticals, Inc.'s Price Target?
The price target for Regeneron Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $804.96 according to 23 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is REGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Regeneron Pharmaceuticals, Inc. is a Buy. 15 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of REGN?
You can purchase shares of Regeneron Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regeneron Pharmaceuticals, Inc. shares.
-
What Is The Regeneron Pharmaceuticals, Inc. Share Price Today?
Regeneron Pharmaceuticals, Inc. was last trading at $800.87 per share. This represents the most recent stock quote for Regeneron Pharmaceuticals, Inc.. Yesterday, Regeneron Pharmaceuticals, Inc. closed at $812.27 per share.
-
How To Buy Regeneron Pharmaceuticals, Inc. Stock Online?
In order to purchase Regeneron Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get REGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
REGN
Sector
P/E ratio
19.45x
24.20x
PEG ratio
5.78x
-0.01x
P/B ratio
2.76x
1.84x
Price / LTM sales
6.28x
1.60x
Growth Metrics
REGN
Sector
Revenue growth
0.9%
4.62%
Earnings growth
18.05%
10.88%
Revenue (5-year growth)
16.71%
6.45%
Earnings forecast
$10.68
-$0.19
Profitability
REGN
Sector
Profitability FY 2024
$11.8B
$3.6M
Return on invested capital
14.07%
-32.02%
Return on assets
11.97%
-28.31%
Return on equity
15.37%
-38%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Jan
30
Estimated Next Earnings Date
Jan
27
Balance Sheet
REGN
Sector
Total cash
$8.5B
$26.1M
Short term investments
$6.5B
$25.7M
Total assets
$37.9B
$76.6M
Long term debt
$2.7B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
